S-Nitrosation of Mitochondrial Complex I Depends on Its Structural Conformation*

Received for publication, September 10, 2007, and in revised form, October 23, 2007
Published, JBC Papers in Press, October 23, 2007, DOI 10.1074/jbc.M707543200

Alexander Galkin1 and Salvador Moncada
From The Wolfson Institute for Biomedical Research, University College London, Gower Street, London WC1E 6BT, United Kingdom

Nitric oxide is known to cause persistent inhibition of mitochondrial respiration as a result of S-nitrosation of NADH:ubiquinone oxidoreductase (complex I) (Clementi, E., Brown, G. C., Feelisch, M., and Moncada, S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7631–7636). Little is known about whether such nitrosation occurs in physiological conditions and, if so, what are the possible cellular mechanisms. We have now found that the conformational state (active/deactive transition (Vinogradov, A. D. (1998) Biochim. Biophys. Acta 1364, 169–185)) of mitochondrial complex I is an important factor for the interaction of the enzyme with nitrosothiols and peroxynitrite. Only the deactivated, idle form of complex I was susceptible to inhibition by nitrosothiols and peroxynitrite. In contrast, the active form of the enzyme was insensitive to such treatment. Neither form of complex I was inhibited by nitric oxide itself. Our data suggest that the process of active/deactive transition plays an important role in the regulation of complex I activity and cellular respiration by nitric oxide. The implications of this finding for hypoxic or pathophysiological conditions in vivo are discussed.

Proton-translocating NADH:ubiquinone oxidoreductase (EC 1.6.5.3, complex I or type I NADH dehydrogenase) is the most complex enzyme of the mitochondrial respiratory chain. It is responsible for oxidation of matrix NADH and is the major entry point for electrons to the respiratory chain. Mammalian complex I consists of at least 45 subunits (1), of which more than 30 are so-called “accessory” subunits, not directly involved in catalysis, whose functions are still unclear. Some of them may have a structural role, assisting in the assembly of the enzyme (2), whereas others may be necessary for the fine regulation of the activity of the enzyme in response to signals from the cytoplasm and matrix.

Some years ago inhibition of complex I-mediated respiration was demonstrated in cells after incubation with activated macrophages (3). Following the discovery that nitric oxide (NO)2 is generated endogenously and acts as a biological mediator (4), this inhibition of complex I activity was found to be due to NO (5). An inhibitory effect of the combined action of NO and superoxide anion on complexes I and II was demonstrated in preparations of intact mitochondria. This was shown to be due to peroxynitrite (ONOO−), a compound that explains the NO-dependent inactivation of several components of the respiratory chain (6–8). Our group found that prolonged exposure to high concentrations of NO led to persistent inhibition of complex I, which we attributed to nitrosation of critical thiol residue(s) (9–11), a finding that has been confirmed by other groups (12–16). Although the degree of inhibition of complex I caused by various NO donors and the stoichiometry of the subsequent modification(s) have been investigated, the precise nature of the targeted subunit(s) and the possibility of nitrosation of complex I during physiological processes have not been established.

The catalytic properties of eukaryotic complex I are not simple (for a review see Ref. 17). Two catalytically and structurally distinct forms exist in any given preparation of the enzyme as follows: one is the fully competent, so-called “active” A-form and the other is the disabled, silent, “de-activated” D-form. So-called pseudoreversible A/D transitions have been described in mammalian complex I (18) and other eukaryotic complex I (19) and have been reviewed in detail (17, 20). After exposure of idle enzyme preparations (mitochondria (21), submitochondrial particles (SMP) (18), or purified complex I (22)) to elevated but physiological temperatures (>30 °C) in the absence of substrate, when catalytic turnover cannot occur, the enzyme converts to the D-form. In such a preparation there is a considerable lag phase during the continuous assay of the NADH:ubiquinone oxidoreductase reaction. Addition of a small (5–10 μM) pulse of NADH before the assay results in activation of the enzyme after several slow turnovers when NADH is oxidized by the quinone. This eliminates the lag phase, and the enzyme becomes fully active and catalyzes oxidation of NADH at a linear rate (18, 22). Therefore, the final zero-order steady state reaction rates for both forms of the enzyme are the same and depend only on the amount of the enzyme added. In the presence of divalent cations (Mg2+ and Ca2+), or at alkaline pH, the activation takes longer, and the lag phase is more pronounced. Divalent cations have no effect on the activity of the A-form.

The high activation energy (270 kJ/mol) of the deactivation process (22) indicates the occurrence of major conformational transitions of complex I during the process.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence should be addressed: The Wolfson Institute for Biomedical Research, University College London, Gower Street, London WC1E 6BT, United Kingdom, Fax: 44-20-7209-0470; E-mail: a.galkin@ucl.ac.uk.

2 The abbreviations used are: NO, nitric oxide; ONOO−, peroxynitrite; CPTIO, 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazolin-1-oxyl-3-oxide; DETA-NO, (Z)-(1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]-diazen-1-ium-1,2-diolate; DTNB, 5,5′-dithiobis-(2-nitrobenzoate); DTT, dithiothreitol; GSN0, 5-nitroso glutathione; HAR, hexaaminemethenyl-um(III) chloride; NEM, N-ethylmaleimide; Q1, 2,3-dimethoxy-5-methyl-6-(3-methyl-2-butenyl)-1,4-benzoquinone; SIN-1, linsidomine; SMP, submitochondrial particles; SNAP, 5-nitroso-N-acetylpenicillamine; SOD, superoxide dismutase.
changes in the organization of the enzyme. However, until now, the only conformational difference observed between these two forms is the number of cysteine residues exposed at the surface of the enzyme (23, 24). Treatment of the D-form of complex I with the sulfhydryl reagents NEM or DTNB irreversibly blocks critical cysteine residue(s), abolishing the ability of the enzyme to respond to activation, thus inactivating it irreversibly. The A-form of complex I is insensitive to sulfhydryl reagents. It has been shown that modification of a cysteine residue(s) of a single subunit with an apparent mass of 15 kDa is responsible for the irreversible inactivation of the D-form by NEM (23). In the A-form of complex I this subunit is not accessible to any covalent modification, accounting for the insensitivity of this form to NEM.

Despite advanced biochemical analysis of the kinetic behavior of both forms of complex I (20), the functional role of the observed heterogeneity has not yet been explained. We have now investigated the effect of nitrosothiols and ONOO• on the A- and D-forms of the enzyme. We have found that only the conformationally modified D-form of complex I is a target for nitrosothiols and ONOO•, whereas the active form is insensitive to these compounds. Furthermore, we demonstrate that there are NO-dependent biochemical mechanisms that can influence the equilibrium between the A- and D-forms. It is possible that A/D transitions of complex I take place in certain pathophysiolog-ical situations, making this enzyme an early mitochondrial target for nitrosative stress.

MATERIALS AND METHODS

Bovine heart SMP were prepared according to standard procedure (18) and stored in liquid nitrogen. As predicted from earlier studies (25), around 40% of complex I in our preparation was present in the D-form because of the temperature conditions during purification.

To prepare SMP in which complex I is present almost entirely in the D-form, an aliquot of frozen membranes was thawed, diluted to 5 mg/ml with standard medium (including 0.25 M sucrose, 50 mM Tris-HCl (pH 8.5), 0.2 mM EDTA, 0.1 mM DTPA, 10 μM neocuprine supplemented with 1 mM malonate for activation of succinate dehydrogenase (26) and 5 mM MgCl₂), and incubated at 35 °C for 1 h. This treatment resulted in almost complete deactivation of complex I. The resulting SMP were diluted twice with the same buffer at pH 8.8 and incubated aerobically for 20 min at room temperature with 1% ethanol and 400 μM NAD⁺ while being constantly stirred. To obtain SMP in which complex I is present in the A-form, alcohol dehydrogenase (100 μg/ml from Saccharomyces cerevisiae; Sigma) was added to the above mixture. During a 20-min incubation with alcohol dehydrogenase, the substoichiometric amounts of NADH produced by the regeneration system were oxidized by complex I; this treatment resulted in full activation and maintained the enzyme in the A-form when kept at 25 °C. Such treatment was found to be more efficient at preserving complex I in its A-form at physiological temperatures than the previously described incubation of SMP with slowly oxidized NADPH (23).

Oxidation of NADH was determined spectrophotometrically (using a Varian Cary 4000) as a decrease in absorption at 340 nm with 200 μM NADH in the standard assay medium (pH 7.0) containing SMP (10–25 μg of protein/ml). As additional measurements of complex I activity, NADH-Q₁ or NADH:HAR oxidoreductase reductase were assayed in the presence of 1 mM cyanide with the addition of 100 μM Q₁ or 2 mM HAR, respectively. If the measurement of full NADH:oxidase activity of the D-form of complex I was required, the enzyme was “activated” by a 10 μM pulse of NADH added directly to the spectrophotometric cuvette, and then full NADH oxidase or NADH:Q₁ reductase was assayed.

Solutions of GSNO, SNAP, DETA-NO, and SIN-1 were prepared freshly before the experiments. Peroxynitrite was synthesized according to a previously published protocol (27).

All chemicals were purchased from Sigma except SIN-1, which was from Invitrogen. Protein content was determined with a Biuret assay. Data are presented as means ± S.E. (n >3). The experimental details are described in the legends to figures.

RESULTS

NADH Regeneration System; Sensitivity of A- and D-forms to NEM—Because of the fast thermally dependent spontaneous transition of the enzyme to the D-form, the maintenance of the enzyme in its active state at temperatures of >20 °C requires special conditions. An alcohol dehydrogenase/ethanol regeneration system for NADH (28) was therefore developed and successfully implemented to keep the enzyme in the A-form. The below-Km concentrations of NADH generated by the metabolism of ethanol by alcohol dehydrogenase were continuously oxidized by complex I of the SMP, maintaining the enzyme at a constant turnover even at temperatures above 25 °C. Fig. 1 demonstrates the dramatic difference in sensitivity to NEM of the A- and the D-form of the enzyme. Addition of NEM had only a slight inhibitory effect on the NADH oxidase activity of the A-form, whereas it rapidly inhibited the enzyme activity of the D-form. Thus, upon deactivation, complex I appeared to become sensitive to cysteine modification.

Effect of Low Molecular Weight Nitrosothiols on Complex I—Fig. 2 demonstrates a dramatic difference in sensitivity of the A- and the D-form of complex I toward S-nitrosoglutathione (GSNO)
or S-nitroso-N-acetylpenicillamine (SNAP) (Fig. 2, A and B, respectively). Only the D-form was inhibited by GSNO or SNAP, whereas the A-form was insensitive to these nitrosating agents. The inhibitory effect of GSNO on NADH oxidase activity was similar when NADH:Q$_1$ reductase activity was measured, indicating a direct effect on complex I and not on downstream components of the respiratory chain (Table 1). Furthermore, the oxidation of NADH by the artificial acceptor HAR was not affected by treatment with GSNO, showing that the content of complex I in the SMP was unchanged.

During decomposition low molecular weight nitrosothiols such as GSNO and SNAP can generate free NO in the solution. Complex I can be modified either by transfer of NO$^+$ or via direct nitrosation by the NO generated. To distinguish between these two mechanisms, additional assays were conducted (see Table 1). We found that the addition of 1 mM CPTIO, a potent scavenger of NO ($k \sim 10^6 \text{ M}^{-1} \text{s}^{-1}$) (29), did not change the inhibitory action of GSNO on the D-form of the enzyme. CPTIO alone has no effect on the activity of the D-form (not shown). In contrast with GSNO and SNAP, prolonged incubation (>2 h) of SMP with 2 mM DETA-NO did not affect the NADH oxidase activity of the D-form of complex I, neither did reduced nor oxidized glutathione (1 mM) (Table 1). Under the same experimental conditions, none of the above treatments had any effect on the A-form of the enzyme (not shown).

Because S-nitrosothiols are sensitive to reducing agents, following treatment with GSNO the inhibited D-form of the enzyme was washed to remove excess GSNO, resuspended in the same medium, and treated with reducing agents. Addition of DTT (1 mM) or GSH (1 mM) led to a significant recovery of the NADH-dependent activities (Table 2). Copper ions are known to catalyze the fast decomposition of S-nitrosothiols, and the reversal of the inhibition was found to be greater when SMP were incubated together with copper and GSH (Table 2).

**Effect of Peroxynitrite on Complex I**—Peroxynitrite is known to nitrate or nitrosate amino acids such as tyrosine (30), to oxidize protein or non-protein thiols (31), and to cause inhibition of complex I in cell (9) mitochondria (7, 12) and SMP (13). The effect of ONOO$^-$ on the A- and D-forms of complex I is shown in Fig. 3A. Addition of ONOO$^-$ directly to the spectrophotometric cuvette had only a small effect on the NADH oxidase activity of the A-form, whereas that of the D-form was significantly inhibited (Fig. 3A). The succinate oxidase reaction was also affected by ONOO$^-$ but to a lesser extent (not shown). Addition of GSH (0.5 mM) to the buffer protected the D-form from inhibition by ONOO$^-$, respectively.

Upon decomposition SIN-1 generates both superoxide anion and NO and is commonly used as a donor of ONOO$^-$. Addition of SIN-1 (0.5 mM) had no effect on the A-form but significantly inhibited the activity of the D-form of the enzyme (Fig. 3B). Addition of 200 units/ml bovine liver SOD in the incubation mixture protected the D-form from SIN-1-induced inhibition (Fig. 3B).
Nitrosation of Complex I

We investigated whether ONOO\(^{-}\) targets the same cysteine residue by treating the D-form with DTNB and then with ONOO\(^{-}\). Subsequent removal of the DTNB by adding DTT did not restore the enzyme activity, indicating that the effect of ONOO\(^{-}\) cannot be explained simply by modification of the only critical cysteine involved in A/D transition (Fig. 4).

**DISCUSSION**

Our present results confirm previous observations on the inhibition of complex I by nitrosating agents (9, 12, 13, 15, 32). Furthermore, they show that the susceptibility of complex I to inhibition is dependent on the exposure of a crucial cysteine residue, which is characteristic of this protein in its de-activated form. The mechanism by which inhibition takes place may be through S-nitrosation, S-glutathionylation, or both (33). Protein S-nitrosation can result from a transnitrosation reaction, in which a nitrosonium ion is directly transferred from GSNO to another protein cysteine residue. Alternatively, the incubation of GSNO and a cysteine-containing protein can produce a mixed disulfide by a S-glutathionylation mechanism. However it has been shown that the glutathionylation activity of GSNO solutions can be explained by the formation of various decomposition products such as glutathione thiosulfinate or thiosulfonate (33, 34); therefore, it is not likely that freshly prepared GSNO solution is a good glutathionylating agent. Furthermore, S-glutathionylation (or S-thiolation in general) is a much slower process than S-nitrosation. Incubation of GSNO-inhibited complex I with glutathione transferase did not result in recovery of enzymatic activity (not shown). In addition, inhibition of complex I by SNAP, which is known to be a pure nitrosating agent (35), progresses at the same rate as that of GSNO. These observations, together with the fact that the inhibition by both agents was reversed by copper ions (Table 2) and that glutathione alone, whether reduced or oxidized, had no effect on either form of complex I, strongly support S-nitrosation as the mechanism of GSNO- and SNAP-induced inhibition.

In contrast, neither DETA-NO on its own nor SIN-1 in the presence of SOD was able to inhibit complex I. This, together with the fact that in the dark when chelating agents are present GSNO is fairly stable (i.e. does not release NO) and that its inhibitory action was not affected by CPTIO, suggests that the inhibition of complex I by GSNO or SNAP most likely occurs via a transnitrosation mechanism.

Peroxynitrite is a potent oxidant for various amino acid residues, with its highest reactivity toward cysteine (36). Our results show that ONOO\(^{-}\) is a rapid and irreversible inhibitor of complex I activity, as has been reported for rat brain SMP (6). We were unable to see any reversal of the inhibition of ONOO\(^{-}\) or SIN-1 by the reducing agents used. Furthermore, blocking of the crucial cysteine residue (as well as many other cysteines) of deactivated complex I with DTNB did not protect the enzyme from inhibition by ONOO\(^{-}\). This suggests that inhibition of complex I by ONOO\(^{-}\) may be caused by modification of other amino acid residue(s) or protein disulfide bond(s) besides the cysteine involved in the A/D transition.

Oxidation of NADH by the artificial acceptor hexaamine-ruthenium (HAR) was not affected by treatment with nitroso-thiol agents. This is in agreement with previous results with NADH:ferricyanide reductase (8). Because the D-form of the enzyme is capable of catalyzing the NADH:HAR reductase reaction, we can assume that nitrosation of the D-form did not cause significant changes in the structure of the D-form peripheral domain of the enzyme or result in disruption of iron-sulfur clusters, and therefore complex I retains its integrity upon treatment.

In bovine heart SMP or mitochondria it is known that ~16 and 25 free SH groups per mg of protein, respectively, are avail-
Nitrosation of Complex I

able for covalent modification, although not all of them belong to complex I (24, 37). Only 35% inhibition of complex I activity upon nitrosation of 10–15 cysteine residues of the enzyme has been found in mitochondria (16). This probably indicates that most of the modifications are not relevant for the catalytic properties of the enzyme. Although treatment of the A-form of the enzyme with nitrosating agents did not affect its catalytic properties, as functionally assessed by various activity measurements, this treatment undoubtedly resulted in modification of many cysteine-containing subunits. As shown before (23) and in this work, the A-form of complex I is insensitive to treatment even by millimolar concentrations of NEM. Most likely, the modification of almost all the surface-exposed SH groups in the active form of complex I by alkylation or nitrosation does not affect the physiological activity of the enzyme. This probably accounts for the minor degree of inhibition of complex I by GSNO (16) or ONOO− (38) in isolated mitochondria, where complex I is mostly present in its active form. However, the modification of only one cysteine residue of the transmembrane subunit ND3, which becomes exposed to the matrix side of complex I after deactivation, fully inhibits the enzyme.3 This different sensitivity of the two forms of complex I to nitrosating agents could explain the difference in the degree of inhibition obtained by various research groups.

Although the existence of the A/D transition has been established in different preparations of complex I, the physiological relevance of this process has not been investigated. It is curious that at physiological temperatures the enzyme is required to expend some of the energy released in the NADH:ubiquinone reductase reaction to maintain a catalytically competent conformational state. It is possible that transition from the A- to D-form of complex I may take place during pathological conditions when the turnover of the enzyme is limited at physiological temperatures, such as during hypoxia or when the NO:oxygen ratio increases (metabolic hypoxia) (39). In such a situation the spontaneous deactivation of complex I would result in increasing sensitivity to nitrosating and oxidizing agents such as GSNO or ONOO−, followed by blocking of the enzyme in the D-state. The details of these reactions have yet to be established.

Inhibition of complex I by S-nitrosation has been implicated in a number of pathologies, including Huntington, Alzheimer, and Parkinson diseases. Furthermore, decreased complex I activity has been reported in skeletal muscle biopsies taken from critically ill patients in septic shock (40). Ischemia-specific post-translational covalent modifications of several subunits of complex I have also been found recently after ischemia/reperfusion heart injuries (41), and the physiological occurrence of two forms of complex I and their interconversion during ischemia/reperfusion has been shown in studies ex vivo (42, 43). The inactivation of complex I may indeed contribute to the reduction of contraction of the heart during ischemic preconditioning, septic shock, and myocarditis (44). Because NO is capable of interacting with mitochondrially produced superoxide anion before the latter can be converted by SOD to hydrogen peroxide (45, 46), it is tempting to speculate that superoxide production in pathological conditions and in the presence of NO (47) would result in formation of ONOO− in the mitochondrial matrix followed by irreversible inhibition of the D-form of complex I that may accumulate during hypoxic conditions.

Acknowledgment—We are grateful to Annie Higgs for help in the preparation of this manuscript.

REFERENCES

1. Carroll, J., Fearnley, I. M., Skehel, J. M., Shannon, R. J., Hirst, J., and Walker, J. E. (2006) J. Biol. Chem. 281, 32724–32727

2. Vogel, R., Nijtmans, L., Ugalde, C., Van den Heuvel, L., and Smeitink, J. (2004) Curr. Opin. Neurol. 17, 179–186

3. Granger, D. L., and Lehninger, A. L. (1982) J. Cell Biol. 95, 527–535

4. Palmer, R. M., Ferrige, A. G., and Moncada, S. (1987) Nature 327, 524–526

5. Stuehr, D. J., and Nathan, C. F. (1989) J. Exp. Med. 169, 1543–1555

6. Lizzioain, I., Moro, M. A., Knowles, R. G., Darley-Usmar, V., and Moncada, S. (1996) Biochem. J. 314, 877–880

7. Radi, R., Rodriguez, M., Castro, L., and Telleria, R. (1994) Arch. Biochem. Biophys. 308, 89–95

8. Cassina, A., and Radi, R. (1996) Arch. Biochem. Biophys. 328, 309–316

9. Clementi, E., Brown, G. C., Feelisch, M., and Moncada, S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7631–7636

10. Beltran, B., Orsi, A., Clementi, E., and Moncada, S. (2000) Br. J. Pharmacol. 129, 953–960

11. Orsi, A., Beltran, B., Clementi, E., Hallen, K., Feelisch, M., and Moncada, S. (2000) Biochem. J. 346, 407–412

12. Borutaite, V., Budriunaite, A., and Brown, G. C. (2000) Biochim. Biophys. Acta 1459, 405–412

13. Riobo, N. A., Clementi, E., Melani, M., Boveris, A., Cadenas, E., Moncada, S., and Poderoso, J. J. (2001) Biochem. J. 359, 139–145

14. Pearce, L. L., Kanai, A. J., Epperly, M. W., and Peterson, J. (2005) Nitric Oxide 13, 254–263

15. Dahm, C. C., Moore, K., and Murphy, M. P. (2006) J. Biol. Chem. 281, 10056–10065

16. Burwell, L. S., Nadtochiy, S. M., Tompkins, A. J., Young, S., and Brookes, P. S. (2006) Biochem. J. 394, 627–634

17. Vinogradov, A. D. (1998) Biochim. Biophys. Acta 1364, 169–185

18. Kotlyar, A. B., and Vinogradov, A. D. (1990) Biochim. Biophys. Acta 1019, 151–158

19. Maklashina, E., Kotlyar, A. B., and Cecchini, G. (2003) Biochim. Biophys. Acta 1606, 95–103

20. Vinogradov, A. D., and Grivennikova, V. G. (2001) IUBMB Life 52, 129–134

21. Grivennikova, V. G., Kapustin, A. N., and Vinogradov, A. D. (2001) J. Biol. Chem. 276, 9038–9044

22. Maklashina, E. O., Sled’, V. D., and Vinogradov, A. D. (1994) Biokhimia 59, 946–957

23. Gavrikova, E. V., and Vinogradov, A. D. (1999) FEBS Lett. 455, 36–40

24. Gostimskaya, I. S., Cecchini, G., and Vinogradov, A. D. (2006) Biochim. Biophys. Acta 1757, 1155–1161

25. Vinogradov, A. D., Gavrikova, E. V., Grivennikova, V. G., Zharova, T. V., and Zakharova, N. V. (1999) Biochim. Biophys. Acta (Moscow) 64, 136–152

26. Kotlyar, A. B., and Vinogradov, A. D. (1984) Biochim. Biophys. Acta 784, 24–34

27. Hughes, M. N., and Nicklin, H. G. (1968) J. Chem. Soc. 2, 450–452

28. Hayes, J. E., and Velik, S. F. (1954) J. Biol. Chem. 207, 225–244

29. Akaike, T., Yoshida, M., Miyamoto, Y., Sato, K., Kohno, M., Sasamoto, K., Miyazaki, K., Ueda, S., and Maeda, H. (1993) Biochemistry 32, 827–832

30. Beckman, J. S., and Koppenol, W. H. (1996) Am. J. Physiol. 271, C1424–C1437

31. Radi, R., Beckman, J. S., Bush, K. M., and Freeman, B. A. (1991) J. Biol.

3 A. Galkin, M. Björn, I. Wittig, M. Karas, H. Schägger, A. Vinogradov, and U. Brandt, manuscript in preparation.
32. Stadler, J., Billiar, T. R., Curran, R. D., Stuehr, D. J., Ochoa, J. B., and Simmons, R. L. (1991) Am. J. Physiol. 260, C910–C916
33. Giustarini, D., Milzani, A., Aldini, G., Carini, M., Rossi, R., and Dalle-Donne, I. (2005) Antioxid. Redox. Signal. 7, 930–939
34. Tao, L., and English, A. M. (2004) Biochemistry 43, 4028–4038
35. Konorev, E. A., Kalyanaraman, B., and Hogg, N. (2000) Free Radic. Biol. Med. 28, 1671–1678
36. Alvarez, B., Ferrer-Sueta, G., Freeman, B. A., and Radi, R. (1999) J. Biol. Chem. 274, 842–848
37. Beer, S. M., Taylor, E. R., Brown, S. E., Dahm, C. C., Costa, N. J., Runswick, M. J., and Murphy, M. P. (2004) J. Biol. Chem. 279, 47939–47951
38. Tompkins, A. J., Burwell, L. S., Digerness, S. B., Zaragoza, C., Holman, W. L., and Brookes, P. S. (2006) Biochim. Biophys. Acta 1762, 223–231
39. Moncada, S., and Erusalimsky, J. D. (2002) Nat. Rev. Mol. Cell Biol. 3, 214–220
40. Brealey, D., Brand, M., Hargreaves, L., Heales, S., Land, J., Smolenski, R., Davies, N. A., Cooper, C. E., and Singer, M. (2002) Lancet 360, 219–223
41. White, M. Y., Tchen, A. S., McCarron, H. C., Hambly, B. D., Jeremy, R. W., and Cordwell, S. J. (2006) Proteomics 6, 6221–6233
42. Maklashina, E., Shet, Y., Zhou, H. Z., Gray, M. O., Karliner, J. S., and Cecchini, G. (2002) Biochim. Biophys. Acta 1556, 6–12
43. Maklashina, E., Kotlyar, A. B., Karliner, J. S., and Cecchini, G. (2004) FEBS Lett. 556, 64–68
44. Monnet, X., Ghaleh, B., Lucas, L., Colin, P., Zini, R., Hittinger, L., and Berdeaux, A. (2006) Cardiov. Res. 70, 391–398
45. Cudd, A., and Fridovich, I. (1982) J. Biol. Chem. 257, 11443–11447
46. Huie, R. E., and Padmaja, S. (1993) Free Radic. Res. Commun. 18, 195–199
47. Palacios-Callender, M., Quintero, M., Hollis, V. S., Springett, R. J., and Moncada, S. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 7630–7635